Their primary mechanisms of action include: Enhancing insulin secretion from pancreatic beta cells in a glucose-dependent manner, which generally reduces the risk of hypoglycaemia (though this risk increases when combined with insulin or sulfonylureas) Suppressing glucagon release from pancreatic alpha cells, thereby reducing hepatic glucose production Slowing gastric emptying , which prolongs satiety and reduces postprandial glucose excursions Acting on appetite centres in the hypothalamus to reduce hunger and food intake These combined effects lead to improved glycaemic control in people with type 2 diabetes and significant weight reduction in those prescribed these medications for obesity management
FDA received more than 320 reports of adverse events associated with compounded tirzepatide as of early 2025, reflecting both the scale of compounding and the quality issues that arose in less rigorously controlled production environments
And that's also against a backdrop of what we've been seeing on the economic side and what your data is reflecting, which is that the consumer sentiment metrics are actually ticking up slightly from their lows
10.1056/NEJMoa1612917 33 HomeP
Clean eating alone rarely reverses underlying feedback loop glitches
The GLP1 class of antidiabetic drugs is growing at a fast pace (green line in the figure below)
